KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $5.1 billion.

  • Abbott Laboratories' Cost of Revenue rose 802.47% to $5.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 billion, marking a year-over-year increase of 556.22%. This contributed to the annual value of $18.7 billion for FY2024, which is 406.68% up from last year.
  • As of Q3 2025, Abbott Laboratories' Cost of Revenue stood at $5.1 billion, which was up 802.47% from $4.9 billion recorded in Q2 2025.
  • Abbott Laboratories' Cost of Revenue's 5-year high stood at $5.1 billion during Q3 2025, with a 5-year trough of $4.3 billion in Q1 2023.
  • In the last 5 years, Abbott Laboratories' Cost of Revenue had a median value of $4.6 billion in 2023 and averaged $4.7 billion.
  • As far as peak fluctuations go, Abbott Laboratories' Cost of Revenue surged by 5160.89% in 2021, and later crashed by 1315.42% in 2023.
  • Over the past 5 years, Abbott Laboratories' Cost of Revenue (Quarter) stood at $4.8 billion in 2021, then dropped by 3.63% to $4.6 billion in 2022, then fell by 0.81% to $4.6 billion in 2023, then increased by 8.47% to $4.9 billion in 2024, then rose by 2.69% to $5.1 billion in 2025.
  • Its Cost of Revenue was $5.1 billion in Q3 2025, compared to $4.9 billion in Q2 2025 and $4.5 billion in Q1 2025.